The Anticancer Drugs
This text offers an up-to-date review of the field of cancer chemotherapy, including some of the new approaches to biological treatments of cancer and potential targets for new drug design. A detailed description of the pharmacology, mechanisms of action, toxicity, resistance mechanisms, and clinical usefulness of each class of drugs is given. The authors emphasize concepts involved in determining the mechanism of action and development of resistance, the determinants of drug responsiveness to chemotherapeutic agents, and a rationale for their clinical use in various types of cancer.
The text is organized in a way that makes it easy for the reader to conceptualize how drugs work and categorize them by their mechanism of action. It facilitates an understanding of the rationale for chemotherapy with respect to the biology of the cancer cell and to tumor growth kinetics. Drawing on the fields of authors draw on the fields of medicinal chemistry, pharmacology, biochemistry, cell biology, molecular biology, and clinical medicine, this timely book is extensively referenced and provides a historical background for the development of each class of drugs.
Відгуки відвідувачів - Написати рецензію
Не знайдено жодних рецензій.
The Cancer Problem
Some Milestones in the Development of Cancer Chemotherapy
Resistance to Anticancer Drugs
THE ANTICANCER DRUGS
Covalent DNA Binding Drugs
Noncovalent DNA Binding Drugs
Inhibitors of Chromatin Function
Інші видання - Показати все
acid activity acute administration adriamycin alkylating agents anthracycline antibodies anticancer drugs antigen antitumor ara-C binding Biochem Biol bleomycin bone marrow breast cancer cancer cells Cancer Chemother Cancer Res Cancer Treat carcinoma cell lines cellular Chem chemotherapy cisplatin Clin clinical combination complex compounds cross-links cyclophosphamide cytotoxic dacarbazine dactinomycin decreased DHFR disease dose doxorubicin drug resistance effect enzyme estrogen etoposide factors folate FUra gene glutathione growth guanine half-life hepatic high-dose Hodgkin's hormone human inhibition inhibitors injection intravenous kinase leukemia levels liver lung lymphocytes lymphoma mechanism melphalan metabolism metabolites metastatic methotrexate mice microtubule mithramycin mitomycin mitoxantrone multidrug resistance mutation Natl nitrogen mustard nitrosoureas normal nucleotide occur Oncol ovarian P-glycoprotein patients pharmacokinetics Pharmacol pharmacology phase plasma procarbazine produced protein purine reaction receptor reductase regimens renal response shown steroid strand studies taxol Ther therapeutic therapy thymidylate tion tissue topoisomerase topoisomerase II toxicity treatment tumor tumor cells vinblastine vincristine vitro vivo